News
StockStory.org on MSN21h
SRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative DelaysBiotech company Sarepta Therapeutics (NASDAQ:SRPT) reported Q1 CY2025 results , with sales up 80.2% year on year to $744.9 ...
1d
Clinical Trials Arena on MSNSarepta reports outcomes from trial of Duchenne muscular dystrophy therapyIn cohort 6, subjects aged two years old at the time of treatment showed a mean expression of 93.87% of normal dystrophin ...
Taking center stage at the American Society of Gene and Cell Therapy meeting was the first-ever reported case of a ...
Since Elevidys' accelerated approval in 2023, experts have been clamoring for more data, particularly in older and ...
Sarepta has submitted a request to the FDA to include the death case in Elevidys’ label, and the agency plans to review the ...
Uncertainty around ELEVIDYS sales impact Sarepta Therapeutics, Inc. Click here to find out why I downgraded SRPT stock to a ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported new ...
Already facing headwinds caused by a patient’s death and treatment delays, the biotech now may have to contend with a less ...
GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that ...
Sarepta Therapeutics Q1 2025 revenue beat expectations, but EPS missed, and cash reserves dropped significantly. Click here ...
“For nearly a decade, Sarepta has been a leader in advancing the treatment of Duchenne muscular dystrophy through innovative treatment options. With the approval of ELEVIDYS in Japan, children ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results